Rheumatoid arthritis patients aged 65 years or older experience a similar response to treatment with golimumab plus methotrexate compared with younger patients, suggests a post-hoc analysis of the GO-FURTHER trial.
Combining denosumab with high-dose rather than standard-dose teriparatide results in greater increases in spine and hip bone mineral density in postmenopausal women with osteoporosis, phase IV study data show.
Low-intensity warfarin treatment has not demonstrated noninferiority to standard-intensity warfarin for the prevention of venous thromboembolism among older people undergoing hip or knee replacement surgery in a randomized controlled trial.
The low-dose recombinant human interleukin IL-2 therapy aldesleukin has a favorable safety profile and may restore regulatory T-cell homeostasis in people with systemic lupus erythematosus, suggest findings from a proof-of-concept phase I/IIa clinical trial.
Adalimumab, used with or without concurrent methotrexate, appears to be well tolerated among children with polyarticular‐course juvenile idiopathic arthritis, 7-year data from the STRIVE registry show.
Previous exposure to multiple conventional DMARDs is associated with a blunted response to treatment with adalimumab plus methotrexate among patients with rheumatoid arthritis, indicate findings from a post-hoc analysis.
Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.
The ACR, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network have issued updated recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.